| A. muciniphila | Akkermansia muciniphila |
| ADT | Androgen deprivation therapy |
| AR | Androgen receptor |
| AHR | Aryl hydrocarbon receptor |
| CRPC | Castration-resistant prostate cancer |
| Dehydroepiandrosterone | DHEA |
| FMT | Fecal microbiota transplantation |
| GI | Gastrointestinal |
| GZMB | Granzyme B |
| GM | Gut microbiome |
| HFD | High-fat diet |
| HSPC | Hormone-sensitive prostate cancer |
| ICI | Immune checkpoint inhibitors |
| IGF-1 | Insulin-like growth factor 1 |
| IL-2 | Interleukin-2 |
| IL-6 | Interleukin-6 |
| IL-12 | Interleukin-12 |
| LPS | Lipopolysaccharide |
| mTOR | Mechanistic target of rapamycin |
| NK | Natural killer |
| PAMPs | Pathogen-associated molecular patterns |
| PRRs | Pattern-recognition receptors |
| PD | Pharmacodynamics |
| PK | Pharmacokinetics |
| PTEN | Phosphatase and tensin homolog |
| PI3K | Phosphatidylinositol 3-kinase |
| PAHs | Polycyclic aromatic hydrocarbons |
| PIA | Proliferative inflammatory atrophy |
| PIN | Prostatic intraepithelial neoplasia |
| PSA | Prostate specific antigen |
| SCC | Prostatic small cell carcinoma |
| AKT | Protein kinase B |
| RT | Radiotherapy |
| SCFAs | Short-chain fatty acids |
| TPH1 | Tryptophan hydroxylase 1 |
| TNF | Tumor necrosis factor |
| TME | Tumor-promoting microenvironment |